HOSE: DCL Statistics

Total Valuation

Cuu Long Pharmaceutical JSC has a market cap or net worth of VND 1.94 trillion. The enterprise value is 2.48 trillion.

Market Cap	1.94T
Enterprise Value	2.48T

Important Dates

The next estimated earnings date is Friday, January 24, 2025.

Earnings Date	Jan 24, 2025
Ex-Dividend Date	n/a

Share Statistics

Cuu Long Pharmaceutical JSC has 73.04 million shares outstanding. The number of shares has decreased by -0.05% in one year.

Current Share Class	n/a
Shares Outstanding	73.04M
Shares Change (YoY)	-0.05%
Shares Change (QoQ)	+3.90%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	n/a

Valuation Ratios

The trailing PE ratio is 30.49.

PE Ratio	30.49
Forward PE	n/a
PS Ratio	1.63
PB Ratio	1.32
P/TBV Ratio	1.34
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 22.54, with an EV/FCF ratio of -10.25.

EV / Earnings	39.03
EV / Sales	2.09
EV / EBITDA	22.54
EV / EBIT	34.35
EV / FCF	-10.25

Financial Position

The company has a current ratio of 2.27, with a Debt / Equity ratio of 0.51.

Current Ratio	2.27
Quick Ratio	1.41
Debt / Equity	0.51
Debt / EBITDA	6.83
Debt / FCF	-3.11
Interest Coverage	2.62

Financial Efficiency

Return on equity (ROE) is 4.41% and return on invested capital (ROIC) is 2.16%.

Return on Equity (ROE)	4.41%
Return on Assets (ROA)	2.00%
Return on Capital (ROIC)	2.16%
Revenue Per Employee	1.31B
Profits Per Employee	70.31M
Employee Count	930
Asset Turnover	0.53
Inventory Turnover	2.51

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +16.67% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+16.67%
50-Day Moving Average	26,775.00
200-Day Moving Average	26,979.25
Relative Strength Index (RSI)	44.81
Average Volume (20 Days)	281,005

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Cuu Long Pharmaceutical JSC had revenue of VND 1.19 trillion and earned 63.49 billion in profits. Earnings per share was 869.24.

Revenue	1.19T
Gross Profit	220.29B
Operating Income	72.15B
Pretax Income	80.92B
Net Income	63.49B
EBITDA	109.92B
EBIT	72.15B
Earnings Per Share (EPS)	869.24

Full Income Statement

Balance Sheet

The company has 226.89 billion in cash and 750.60 billion in debt, giving a net cash position of -523.72 billion or -7,170.16 per share.

Cash & Cash Equivalents	226.89B
Total Debt	750.60B
Net Cash	-523.72B
Net Cash Per Share	-7,170.16
Equity (Book Value)	1.48T
Book Value Per Share	20,057.18
Working Capital	798.21B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -10.27 billion and capital expenditures -231.47 billion, giving a free cash flow of -241.73 billion.

Operating Cash Flow	-10.27B
Capital Expenditures	-231.47B
Free Cash Flow	-241.73B
FCF Per Share	-3,309.57

Full Cash Flow Statement

Margins

Gross margin is 18.58%, with operating and profit margins of 6.09% and 5.36%.

Gross Margin	18.58%
Operating Margin	6.09%
Pretax Margin	6.83%
Profit Margin	5.36%
EBITDA Margin	9.27%
EBIT Margin	6.09%
FCF Margin	n/a

Dividends & Yields

Cuu Long Pharmaceutical JSC does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.05%
Shareholder Yield	0.05%
Earnings Yield	3.28%
FCF Yield	-12.49%

Stock Splits

The last stock split was on August 4, 2016. It was a forward split with a ratio of 1.4.

Last Split Date	Aug 4, 2016
Split Type	Forward
Split Ratio	1.4

Scores

Cuu Long Pharmaceutical JSC has an Altman Z-Score of 2.52. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.52
Piotroski F-Score	n/a